Deals· August 8, 2026 · 15 min read
Servier's $2.5B Day One deal: tovorafenib (Ojemda) & first EU JCA completion
By Ran Chen#Servier#Day One#Tovorafenib
Day One Biopharmaceuticals acquisition by Servier, tovorafenib (Ojemda) commercialization, and pediatric oncology pipeline.